Acute liver failure (ALF) occurs when an acute injury to the liver is not compensated by the liver’s endogenous regenerative capacity, resulting in impaired liver function. Accelerating the liver’s regenerative capacity by activating the MET-hepatocyte growth factor (HGF) signaling pathway was the aim of this research. AGMB-101, developed by Agomab Therapeutics NV, is an agonist antibody targeting MET that was tested in two murine models of ALF.
Primary sclerosing cholangitis (PSC) is a disease affecting the bile ducts that can lead to end-stage liver disease and cholangiocarcinoma. Patients with this disease lack therapeutic treatment other than liver transplantation.
Cholangiocarcinoma (CCA) is the second most common primary cancer of the liver with a median survival of 25 months. Therapeutic options for CCA are limited and the discovery of new therapeutic approaches is crucial for CCA management.
Collplant Biotechnologies Ltd. and Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University and Sheba Medical Center, have entered into a license and research agreement to codevelop a gut-on-a-chip tissue model for drug discovery and high-throughput screening of drugs.